Search

Your search keyword '"Zhang, Xuyao"' showing total 478 results
Start Over Author "Zhang, Xuyao"
478 results on '"Zhang, Xuyao"'

13. Introduction

Author

Cheung, Paul, primary, George, Ammu, additional, and Zhang, Xuyao, additional

Published
2023
Full Text
View/download PDF

31. All‐Optical Physical Field Recognition Via Sparse Feature Extraction.

Author

Qi, Haotong, Hu, Jianyang, Li, Chang, Zhang, Xuyao, Chen, Chen, Cao, Danlin, Lin, Jie, Wang, Yiqun, and Jin, Peng

Subjects
OPTICAL computing, DIFFRACTIVE optical elements, VECTOR beams, EXPERIMENTAL films, FEATURE extraction
Abstract

Optical computing has been proven to have the ability to process information with ultra‐high speed. Here, an all‐optical feature extraction system via sparse representation (AFE‐SR) is introduced. The AFE‐SR, which is achieved by multiple diffractive optical elements (DOEs), can realize the recognition of generated physical fields with the speed of light. The sparse representation simplifies the target and improves the recognition accuracy. With the mathematical analysis principle of sparse optical features extraction and optical integration, the identification accuracy of the generation of physical fields is 100% in 2100 frames of the experimental videos. The application field of optical computing systems is extended to state recognition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer

Author

Wei,Xiao, Zhao,Yun, Yan,Wenyue, Dai,Qigang, Wu,Hui, Miao,Yang, Huang,Lei, Liu,Qing, Zhang,Xuyao, Wang,Hongxia, Liu,Yanan, Zhang,Linlin, Wei,Xiao, Zhao,Yun, Yan,Wenyue, Dai,Qigang, Wu,Hui, Miao,Yang, Huang,Lei, Liu,Qing, Zhang,Xuyao, Wang,Hongxia, Liu,Yanan, and Zhang,Linlin

Abstract

Xiao Wei,1,* Yun Zhao,1,* Wenyue Yan,2 Qigang Dai,3 Hui Wu,1 Yang Miao,1 Lei Huang,1 Qing Liu,4 Xuyao Zhang,5 Hongxia Wang,1 Yanan Liu,1 Linlin Zhang1 1Department of Pharmacy, The First People’s Hospital of Yancheng, Yancheng No.1 People’s Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, Jiangsu, 224000, People’s Republic of China; 2Department of Oncology, The First People’s Hospital of Yancheng, Yancheng No.1 People’s Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, Jiangsu, 224000, People’s Republic of China; 3Department of Acute Infectious Disease Control and Prevention, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, 210009, People’s Republic of China; 4Department of Pharmacy, Yancheng Maternity and Child Health Care Hospital, Yancheng, Jiangsu, 224000, People’s Republic of China; 5Department of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai, 201203, People’s Republic of China*These authors contributed equally to this workCorrespondence: Linlin Zhang; Yanan Liu, Department of Pharmacy, The First People’s Hospital of Yancheng, Yancheng No.1 People’s Hospital, Affiliated Hospital of Medical School, Nanjing University, Yancheng, Jiangsu, 224000, People’s Republic of China, Email 1515605617@qq.com; lynishot@163.comBackground: Anlotinib and apatinib, both vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs), are clinically established in the treatment of advanced non-small cell lung cancer (NSCLC) in China, with anlotinib emerging as a standard treatment strategy. This study was conducted to evaluate the efficacy and safety of apatinib and anlotinib, and to compare their differences in treating patients with advanced NSCLC.Patients and Methods: We retrospectively analyzed the data of patients with advanced NSCLC t

Published
2024

43. Modeling of the temperature‐dependent tensile strength of polymer considering the effect of the two‐phase transition of glass and rubber phases.

Author

Li, Ying, Zuo, Mini, Mai, Zhipeng, Deng, Qian, Lin, Yi, Zhang, Xuyao, and Li, Weiguo

Subjects
TENSILE strength, GLASS transitions, SHAPE memory polymers, POLYMERS, RUBBER, INORGANIC polymers
Abstract

This study explores the contribution of glass phase and rubber phase to polymer failure, and establishes a theoretical model of temperature‐dependent tensile strength (TDTS) considering the effect of two‐phase transition based on the Force‐heat Equivalence Energy Density Principle (FHEEDP). The model achieves good verification by comparison with the TDTS experimental data of various polymer materials, including epoxy‐based shape memory polymer (SMP), PEEK‐based SMP and CdS/PMMA. The results demonstrate that the model can perform an accurate prediction for the tensile strength of polymer at different temperatures by easily obtainable material parameters. In conclusion, the proposed theoretical model deepens the understanding on the two‐phase transition and their effect on the TDTS, as well as supplies a practical predicted method on the TDTS of polymer, which is crucial for polymer applied in extreme condition. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer.

Author

Huang, Xiting, Wang, Qian, Nan, Yanyang, Zhang, Xuyao, Xu, Ke, Ju, Dianwen, and Ding, Weihong

Subjects
CD47 antigen, PHAGOCYTIC function tests, CHIMERIC proteins, NEOVASCULARIZATION inhibitors, PROTEIN expression, BLADDER cancer
Abstract

Background: Although immunotherapy has shown potential in cancer treatment, current immunotherapeutics for bladder cancer are limited by a low response rate. Therefore, it is necessary to investigate other suitable immunotherapeutic targets and strategies for bladder cancer. Methods: To evaluate whether CD47 could be a suitable target for bladder cancer immunotherapy, CD47 protein expression levels in 116 bladder cancer tissue samples were assessed by IHC staining. In vitro anti-tumor effect of blocking CD47 was examined by phagocytosis assays. In vivo anti-tumor effects of targeting CD47 and angiogenesis were experimented in the HSPCs-CDX model. Results: We find that CD47 is highly expressed in bladder cancer samples and is associated with poor prognosis. Blocking CD47 could enhance the human PBMC-derived macrophages' phagocytosis of T24 (from 10.40% to 29.70%) and 5637 (from 5.31% to 33.52%) human bladder cancer cells, as well as demonstrate anti-tumor effects in the HSPCs-CDX model (tumor growth inhibition rate, TGI: 33.05%). During CD47 treatment, we observed that the level of angiogenesis increased after CD47 blockade, and it might undermine the effect of CD47 immunotherapy. We then combined CD47 blockade with anti-angiogenic drugs to treat bladder cancer and discovered that inhibiting angiogenesis could further improve the anti-tumor effect of CD47 blockade (TGI: 76.39%). Finally, we tested the anti-tumor effect of co-targeting CD47 and angiogenesis using a bispecific fusion protein, SIRPα-VEGFR1, which successfully inhibited tumor growth to a similar extent as a combination therapy. Conclusions: Our study suggests that targeting CD47 could inhibit the growth of bladder cancer by promoting macrophage-mediated anti-tumor immunity. Moreover, blocking CD47 and angiogenesis could achieve a potent anti-tumor effect and could be an effective immunotherapy strategy for bladder cancer. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer.

Author

Wei, Xiao, Zhao, Yun, Yan, Wenyue, Dai, Qigang, Wu, Hui, Miao, Yang, Huang, Lei, Liu, Qing, Zhang, Xuyao, Wang, Hongxia, Liu, Yanan, and Zhang, Linlin

Subjects
NON-small-cell lung carcinoma, APATINIB, NEOVASCULARIZATION inhibitors, BONE metastasis, ANLOTINIB
Abstract

Objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety profile. Results: A total of 145 patients were included in this study. Median PFS (mPFS) was 3.53 months for the apatinib group and 5.3 months for the anlotinib group (HR = 0.59, 95% CI: 0.41– 0.84; P = 0.004), and median OS (mOS) was 7.6 months versus 15.6 months (HR = 0.68, 95% CI: 0.46– 1.00; P = 0.048), which all showed significant differences after adjusting for confounders (P < 0.05). Subgroup analysis revealed that the presence or absence of bone metastases significantly influenced PFS in both treatment groups. The ORR was 3.03% in the anlotinib group versus 10.13% in the apatinib group (P = 0.12), the DCR was 72.73% versus 51.90% (P = 0.21). No unanticipated adverse events (AEs) were observed. The incidence of grade 3– 4 AEs was significantly higher in the apatinib group (31.65% vs 13.64%, P < 0.05). Conclusion: Anlotinib demonstrated greater efficacy and safety compared to apatinib in the treatment of advanced NSCLC, particularly in patients with bone metastases and EGFR(-). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results